Beyond plasma: defining the translation value of epithelial lining fluid exposure profiles for the treatment of pneumonia
Abstract
Background: Plasma pharmacokinetic/pharmacodynamic (PK/PD) targets are a surrogate of pulmonary exposures for pneumonia, despite potential differences in exposures. This study defined free plasma and pulmonary epithelial lining fluid (ELF) PK/PD targets for different antibiotics against Klebsiella pneumoniae (KP) in a preclinical pneumonia model, and assessed the predicted cfu/lung response of human exposures relative to MIC breakpoints.
Method: Secondary analyses were performed on previously published in vivo cfu/lung data generated using 17 KP after administration of different dosing regimens of meropenem, cefiderocol, levofloxacin and tobramycin. Efficacy was evaluated as change in log10 cfu/lung at 24 h. Emax models were fitted to composite cfu data, and plasma and ELF targets were calculated using the Hill equation. The average human plasma and ELF exposures achieved clinically relative to MIC breakpoints were overlaid on the Emax curve to predict corresponding cfu/lung efficacy.
Results: All Emax models had an R2 > 0.85. ELF targets differed from plasma targets and were generally lower (meropenem, cefiderocol and tobramycin), but higher for levofloxacin. Based on average human ELF exposures, the predicted cfu/lung responses of all four antibiotics were ≥1 log10 cfu/lung reduction at susceptible MICs, variable at intermediate MICs and limited at resistant MICs. Based on plasma targets, both meropenem and cefiderocol predicted cfu reduction at resistant breakpoints,…
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.